Antagonist for progestin membrane receptor
2-hydroxypentanoic acid acts as an antagonist to progestin membrane receptors, inhibiting egg cell maturation and ovulation, addressing the lack of known inhibitors and offering a contraceptive solution.
Patent Information
- Application Number
- JP2023079187
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-22
Smart Images

Figure 2024163501000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to antagonists of progestin membrane receptors. [Background technology]
[0002] 17α,20β-dihydroxy-4-prognen-3-one (DHP), a type of steroid hormone, is known as an oocyte maturation-inducing hormone. DHP is an agonist of the membrane progestin receptor (mPR) and induces oocyte maturation by binding to the mPR present on the cell surface of oocytes (Non-Patent Documents 1 to 3).
[0003] mPR is a seven-transmembrane receptor that forms a novel G protein-coupled receptor family consisting of 11 genes showing homology to the AdipoQ receptor, and is named the progestin and adipoQ receptors (PAQR) family. There are five types of mPR molecules, α, β, γ, δ, and ε, which correspond to PAQR7, PAQR8, PAQR5, PAQR6, and PAQR9, respectively. In addition, mPR is conserved in cells of a wide range of vertebrates from humans to fish, and is known to be expressed in various tissues such as the brain and kidney (Non-Patent Documents 4 to 6). The present inventors have succeeded in purifying a steroid membrane receptor with steroid hormone binding activity, making it possible to screen substances using the purified mPR (Patent Document 1).
[0004] It is believed that inhibiting mPR may suppress the maturation of egg cells and reduce the chances of conception, while promoting mPR may promote the maturation of egg cells and increase the chances of conception; however, no naturally occurring substances that act on mPR have been discovered or reported to date (Non-Patent Document 7). [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2015-010064 A [Non-patent literature]
[0006] [Non-Patent Document 1] Y. Zhu et al., "Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes", Proc Natl Acad Sci US A 100(5):2231-2236 (2003). [Non-Patent Document 2] Mika Tokumoto et al., "Cloning and identification of a membrane progestin receptor in goldfishovaries and evidence it is an intermediary in oocyte meiotic maturation", Gen.Comp. Endo. 145(1):101-108 (2006). [Non-Patent Document 3] Md Rezanujjaman et al., "Anagonist for membrane progestin receptor (mPR) induces oocyte maturation and ovulation in zebrafish in vivo", Biochemical and Biophysical ResearchCommunications 529(2):347-352 (2020). [Non-Patent Document 4] Peter Thomas et al., "Steroid and G Protein Binding Characteristics of the Seatrout and Human Progestin Membrane Receptor Subtypes and Their Evolutionary Origins", Endocrinology 148(2):705-718 (2007). [Non-Patent Document 5] Jessica L. Smith et al., "Heterologous expression of human mPRα, mPRβ and mPRγ in yeast confirms their ability to function as membrane progesterone receptors", Steroids 73(11):1160-1173(2008). [Non-Patent Document 6] Yefei Pang et al., "Characterization, Neurosteroid Binding and Brain Distribution of Human Membrane Progesterone Receptors δ and ε (mPRδ and mPRε) and mPRδ Involvement in Neurosteroid Inhibition of Apoptosis", Endocrinology 154(1):283-295 (2013). [Non-Patent Document 7] Peter Thomas, "Membrane Progesterone Receptors (mPRs, PAQRs): Review of Structural and Signaling Characteristics", Cells 2022, 11(11):1785 (2022). [Non-Patent Document 8] Md. Maisum Sarwar Jyoti et al., "Establishment of a steroid binding assay for membrane progesterone receptor alpha (PAQR7) by using graphene quantum dots (GQDs)", Biochemicaland Biophysical Research Communications 592, 1-6 (2022). [Non-Patent Document 9] Toshinobu Tokumoto et al., "Diethylstilbestrolinduces fish oocyte maturation", Proc. Natl. Acad. Sci. USA 101(10):3686-3690 (2004). Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to provide antagonists of progestin membrane receptors. [Means for solving the problem]
[0008] The present inventors have found that the secretions of sea fan (Padina arborescens) have the effect of inhibiting mPR, and further analyzed the active ingredients contained in the secretions, discovering mPR antagonists, thereby completing the present invention.
[0009] The present invention relates to the following [1] to [4]. [1] An antagonist of the progestin membrane receptor, comprising 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof. [2] An inhibitor of the formation of mature egg cells, comprising 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof. [3] An ovulation suppressant containing 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof. [4] A drug described in any one of [1] to [3], which is used for contraception. Effect of the Invention
[0010] According to the progestin membrane receptor antagonist of one embodiment of the present invention, the activation of intracellular signals caused by the binding of a progestin membrane receptor agonist to the progestin membrane receptor can be suppressed. This effect is presumed to be due to the binding of a progestin membrane receptor antagonist, such as 2-hydroxypentanoic acid, to the progestin membrane receptor, thereby suppressing the original effect of the progestin membrane receptor agonist.
[0011] According to the drug for inhibiting egg cell maturation according to one embodiment of the present invention, it is possible to inhibit egg cell maturation. This inhibitory effect on egg cell maturation is presumed to be based on the antagonistic effect of 2-hydroxypentanoic acid or the like on progestin membrane receptors.
[0012] According to an embodiment of the present invention, the ovulation suppressant can suppress ovulation in a subject to which it is administered. This ovulation suppression effect is presumed to be based on the antagonistic effect of 2-hydroxypentanoic acid or the like on the progestin membrane receptor.
[0013] According to one embodiment of the present invention, the drug used for contraception can suppress ovulation in a subject to which it is administered, and as a result, the probability of fertilization and pregnancy in the subject to which it is administered can be reduced. This contraceptive effect is presumed to be based on the antagonistic effect of 2-hydroxypentanoic acid, etc., on progestin membrane receptors. [Brief description of the drawings]
[0014] [Figure 1]FIG. 2 shows a chromatogram of sea fan secretions isolated using TSKgel Protein A-5PW RP Glass in Example 1. [Diagram 2] FIG. 1A shows the results of a test for inhibiting the maturation of zebrafish oocytes using isolated Peak 1 products in Example 2, and FIG. 1B shows the results of a test for inhibiting the maturation of zebrafish oocytes using isolated Peak 2 products in Example 2. [Diagram 3] FIG. 1 shows the results of a zebrafish oocyte maturation inhibition test and an ovulation inhibition test conducted on the isolated Peak2 product in Example 3. [Figure 4] FIG. 1 shows the results of 1H-NMR obtained for an isolated product of Peak 2 in Example 4. [Diagram 5] FIG. 1 shows the results of 13C-NMR obtained for the isolated product of Peak 2 in Example 4. [Figure 6] FIG. 13 shows the results of obtaining DQF-COSY for the isolated Peak 2 product in Example 4. [Figure 7] FIG. 1 shows the results of obtaining TOCSY for the isolated Peak 2 in Example 4. [Figure 8] FIG. 1 shows the results of HMQC obtained for the isolated Peak 2 product in Example 4. [Figure 9] FIG. 1 shows the results of obtaining HMBC for an isolated Peak2 product in Example 4. [Figure 10] FIG. 1 shows the results of a test of (R)-2-HPA and (S)-2-HPA on inhibition of maturation of zebrafish oocytes in Example 5. [Figure 11] FIG. 1 shows the results of evaluating the binding ability of 2-HPA and its analogous compounds to mPR in Example 6. [Figure 12] FIG. 1 shows the results of a test for inhibiting maturation of zebrafish oocytes and a test for inhibiting ovulation of 2-HPA in Example 7. [Figure 13] FIG. 1 shows the results of a maturation inhibition test of goldfish-derived oocytes conducted for 2-HPA and its analogous compounds in Example 8. [Figure 14] FIG. 1 shows the results of a test for inhibiting maturation and ovulation of zebrafish oocytes conducted on 2-HPA and its analogous compounds in Example 9. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The following describes an embodiment of the present invention, but the present invention is not limited to the following embodiment.
[0016] Sea fan (Padina arborescens) is a type of seaweed in the genus Padina, family Padinae, order Dictyotales. Padinas are found in a wide range of areas, including Japan, the Pacific Ocean, and the Indian Ocean.
[0017] The present inventors have demonstrated that the secretion of sea fan has an inhibitory effect on the progestin membrane receptor (mPR) as shown in the examples. Furthermore, the present inventors analyzed the active ingredients in the secretion of sea fan and obtained 2-hydroxypentanoic acid and the like as antagonists of the progestin membrane receptor. In addition, molecules that bind to the ligand binding site of the receptor include agonists, which are molecules that activate downstream intracellular signals by binding to the receptor, and antagonists, which are molecules that do not activate intracellular signals even when bound to the receptor. Among them, antagonists can competitively inhibit the binding of endogenous agonists and receptors, and are therefore widely used as active ingredients in drugs that suppress the activation of downstream intracellular signals of receptors.
[0018] <Progestin membrane receptor antagonist> A first aspect of the present invention is an antagonist of the progestin membrane receptor (mPR) (also referred to as a composition for competitively inhibiting the progestin membrane receptor), which comprises, as an active ingredient, 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof.
[0019] The progestin membrane receptor (mPR) is a seven-transmembrane cell membrane receptor whose existence was reported in 2003 by a group led by Peter Thomas et al. at the University of Texas (Non-Patent Document 1). mPR forms a novel G protein-coupled receptor family consisting of 11 genes showing homology to the AdipoQ receptor, and is named the progestin and adipoQ receptors (PAQR) family. There are five types of mPR molecules, α, β, γ, δ, and ε, which correspond to PAQR7, PAQR8, PAQR5, PAQR6, and PAQR9, respectively. In addition, mPR is conserved in cells of a wide range of vertebrates from humans to fish, and is known to be expressed in various tissues such as the brain and kidney (Non-Patent Documents 4 to 6). The mPR according to one embodiment of the present invention may be at least one selected from the group consisting of mPRα, mPRβ, mPRγ, mPRδ, and mPRε, and in a preferred embodiment, may be at least one selected from the group consisting of mPRα, mPRβ, and mPRγ, and in a more preferred embodiment, may be mPRα.
[0020] In the present specification, the term "progestin membrane receptor antagonist" refers to a preparation containing an mPR antagonist as an active ingredient and used to competitively inhibit mPR. The antagonistic effect on progestin membrane receptor can be confirmed, for example, by a maturation evaluation test of zebrafish oocytes shown in the Examples (see the second aspect of the present invention described later).
[0021] The antagonistic effect of the progestin membrane receptor by an antagonist according to one embodiment of the present invention means that the maturation of oocytes is inhibited by 30% or more, 40% or more, 50% or more, 60% or more, or 70% or more compared to the maturation of oocytes in the absence of the inhibitor, as evaluated by the above method.
[0022] 2-Hydroxypentanoic acid (2-HPA), also known as 2-hydroxyvaleric acid, is a compound represented by the following formula (I). 2-HPA can be purchased from, for example, Fujifilm Wako Pure Chemical Industries, Ltd., Sigma-Aldrich Corporation, etc. As the 2-HPA according to the present invention, for example, a commercially available product may be used, or one synthesized by a method normally performed by a person skilled in the art may be used, or one isolated from the secretion of a sea fan may be used. [ka]
[0023] 2-HPA exists in two enantiomers ((R)-2-HPA and (S)-2-HPA) as shown in the following formula (II). The 2-HPA according to the present invention may be (R)-2-HPA, (S)-2-HPA, or a mixture of the two in any ratio (e.g., racemic mixture). The abundance ratio of (S)-2-HPA in the total of the two enantiomers of 2-HPA according to the present invention may be, for example, 0%, 1% or more, 5% or more, 10% or more, 20% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 80% or more, 90% or more, 95% or more, 99% or more or 100%, or may be 99% or less, 95% or less, 90% or less, 80% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 20% or less, 10% or less, 5% or less, or 1% or less. [ka]
[0024] The antagonist according to one embodiment of the present invention contains 2-HPA in the form of a free form or a salt thereof, an ester, a tautomer, an isotope-labeled compound, a solvate, a cocrystal, a polymorph, a prodrug, or a metabolite. Here, the tautomer, the isotope-labeled compound, the cocrystal, the polymorph, the prodrug, or the metabolite of 2-HPA includes a salt or a solvate thereof. The antagonist according to one embodiment of the present invention may contain one of these, or may contain two or more of them. In a preferred embodiment, the antagonist of the progestin membrane receptor according to the present invention may contain 2-HPA in the form of a free form or a salt thereof, a tautomer, an isotope-labeled compound, or a solvate thereof. In a more preferred embodiment, the antagonist of the progestin membrane receptor according to the present invention may contain 2-HPA in the form of a free form or a salt or a solvate thereof.
[0025] The salt of 2-HPA according to one embodiment of the present invention may be any salt of 2-HPA, and when the mPR antagonist is a pharmaceutical composition, the salt of 2-HPA is preferably a pharma- ceutically acceptable salt of 2-HPA. The pharma- ceutically acceptable salt is not particularly limited as long as it is a salt formed between a 2-HPA carboxylic acid residue and a pharma- ceutically acceptable base (cation), and may be, for example, a sodium salt, a magnesium salt, a potassium salt, a calcium salt, an ammonium salt, a meglumine salt, or an ethanolamine salt of 2-HPA.
[0026] The solvent in the solvate of 2-HPA according to one embodiment of the present invention may be any solvent capable of forming a solvate, and when the mPR antagonist is a pharmaceutical composition, the solvate of 2-HPA is preferably a pharmaceutically acceptable solvate of 2-HPA. Examples of the solvent in the pharmaceutically acceptable solvate include water, ethanol, propanol, isopropanol, diethyl ether, tetrahydrofuran, etc., and preferably water.
[0027] Examples of esters and prodrugs of 2-HPA according to the present invention include the group of compounds represented by the following formula (III). [ka]
[0028] In the case of an ester, R 1 and R 2 For example, each independently represents an alkyl group. In a preferred embodiment of the ester, R 1 and R 2 each independently represents a C1 to C10 alkyl group, more preferably a C1 to C8, C1 to C6 or C1 to C3 alkyl group, and the alkyl group may be linear or branched. 1 and R 2 may each independently be selected from the group consisting of a methyl group, an ethyl group, a propyl group, and a butyl group. In the case of a prodrug, R 1 and R 2 For example, each independently represents a medoxomil group (5-methyl-2-oxo-1,3-dioxol-4-yl group). The ester and prodrug of 2-HPA having the structure represented by the above formula (III) are hydrolyzed by esterase present in the subject to which they are administered, and 2-HPA is released in the subject as a degradation product thereof.
[0029] The content of 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof in the antagonist according to one embodiment of the present invention is, for example, 1% by mass or more, 10% by mass or more, 25% by mass or more, 50% by mass or more, 60% by mass or more, 70% by mass or more, 75% by mass or more, 80% by mass or more, 85% by mass or more, 90% by mass or more, 92% by mass or more, 94% by mass or more, based on the mass of the entire antagonist. It may be 99.5% by mass or less, 99% by mass or less, 98% by mass or less, 97% by mass or less, 95% by mass or more % or less, 93% by mass or less, 91% by mass or less, 85% by mass or less, 80% by mass or less, 75% by mass or less, 70% by mass or less, 60% by mass or less, 50% by mass or less, 30% by mass or less, 15% by mass or less, or 5% by mass or less.
[0030] The antagonist according to one embodiment of the present invention may further contain additives commonly used in the technical field of formulations, such as excipients, buffers, stabilizers, antioxidants, binders, disintegrants, fillers, emulsifiers, and flow additives, in addition to 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof.
[0031] The subject to which the antagonist according to one embodiment of the present invention is administered is not limited as long as it is a eukaryote expressing mPR, and is preferably a vertebrate expressing mPR, and more preferably a mammal or fish expressing mPR. Examples of subjects to which the antagonist is administered include mammals such as humans, mice, rats, rabbits, guinea pigs, horses, pigs, and sheep, and fish such as zebrafish, goldfish, carp, rainbow trout, sea bream, and flounder, and is preferably humans.
[0032] The administration form of the antagonist according to one embodiment of the present invention is not particularly limited, and examples thereof include oral administration, vaginal administration, transbranchial administration, intravenous injection, subcutaneous injection, intramuscular injection, and transdermal administration. When the subject is a mammalian animal, the administration form according to a preferred embodiment may be oral administration or transvaginal administration. When the subject is a fish animal, the administration form according to a preferred embodiment may be oral administration or transbranchial administration. When the antagonist is orally administered to a fish animal, it may be mixed with food.
[0033] The dosage form of the antagonist according to one embodiment of the present invention is not particularly limited, and examples thereof include capsules, liquids, syrups, granules, powders, tablets, pills, oral jellies, inhalants, sprays, gels, creams, lotions, ointments, aerosols, patches, tapes, poultices, injections, vaginal suppositories, and vaginal tablets. When the antagonist according to one embodiment is orally administered to a mammalian animal, the dosage form may be, for example, capsules, liquids, syrups, granules, powders, tablets, pills, oral jelly, or inhalants. When the antagonist according to one embodiment is administered vaginally to a mammalian animal, the dosage form may be, for example, sprays, gels, creams, lotions, ointments, aerosols, patches, tapes, poultices, injections, vaginal suppositories, and vaginal tablets. In addition, the antagonist according to one embodiment of the present invention may be an immediate release formulation or a sustained release formulation. As a specific example of the dosage, for example, when the subject is a human adult female, the daily dosage of the antagonist may be 0.0001 μg to 10,000 mg / day / 60 kg body weight in terms of the amount of active ingredient, and when the subject is a fish animal, the daily dosage of the antagonist may be 0.0001 μg to 10,000 mg / day / g body weight in terms of the amount of active ingredient.
[0034] The antagonist according to the first aspect of the present invention can be used, for example, as a research reagent for evaluating the physiological function of mPR. As a specific example, the antagonist according to the first aspect of the present invention can be administered to a subject to suppress activation of an intracellular signal transmitted by mPR, and then the phenotypic changes or changes in gene and protein expression, etc., that occur in the administered subject can be evaluated. Such evaluation can clarify the effect of the intracellular signal transmitted by mPR on the subject and the expression fluctuations of molecules that contribute to the transmission of the intracellular signal.
[0035] Antagonists according to the first aspect of the invention can be used, for example, to inhibit physiological events that result from the binding of an agonist to the mPR, such as oocyte maturation and ovulation.
[0036] The antagonists according to the first aspect of the invention can be used in screening for other progestin membrane receptor antagonists or progestin membrane receptor enhancers.
[0037] The fact that the antagonist according to the first aspect of the present invention has competitively inhibited mPR can be evaluated, for example, by a method similar to the evaluation method for the inhibitor according to the second or third aspect of the present invention described below.
[0038] <Drugs that inhibit egg cell maturation> A second aspect of the present invention is a drug for inhibiting the formation of mature egg cells (also referred to as a composition for inhibiting the formation of mature egg cells), which contains 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof as an active ingredient.
[0039] The inhibitor according to the second aspect of the present invention and the subjects, administration modes, dosage forms and dosage amounts thereof may be the same as those of the antagonist according to the first aspect of the present invention.
[0040] As used herein, a mature egg cell (ovum, egg, egg) refers to a reproductive cell that is a female gamete in sexually reproducing vertebrates.
[0041] Mature oocytes are formed when primary oocytes stored in the ovaries of female vertebrates undergo meiosis (first meiotic division) to give rise to secondary oocytes, which then undergo further meiosis (second meiotic division). The inhibitor according to the second aspect of the present invention can inhibit the formation of such mature oocytes.
[0042] Without wishing to be bound by any theory, the inhibitor according to the second aspect of the present invention may inhibit the formation of mature oocytes by inhibiting meiotic division I and / or meiotic division II through competitive inhibition of mPR.
[0043] The inhibition of the formation of mature oocytes by the inhibitor according to the second aspect of the present invention can be evaluated, for example, by administering the inhibitor to a subject or oocytes collected from a subject and observing the inhibition of oocyte maturation. For example, utilizing the fact that zebrafish oocytes become transparent due to germinal vesicle breakdown upon maturation, the inhibitor can be evaluated as inhibiting the formation of mature oocytes by observing a decrease in the proportion of oocytes that become transparent upon administration of the inhibitor.
[0044] The inhibitory effect of the inhibitor of the second aspect of the present invention on mature oocytes means that the maturation of oocytes is inhibited by 30% or more, 40% or more, 50% or more, 60% or more, or 70% or more compared to the maturation of oocytes in the absence of the inhibitor, as evaluated by the above-mentioned method.
[0045] A third aspect of the present invention is also referred to as a drug for suppressing ovulation (a composition for suppressing ovulation) containing 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof.
[0046] The inhibitor according to the third aspect of the present invention and its administration target, administration mode, dosage form and dosage amount may be the same as those for the antagonist according to the first aspect of the present invention.
[0047] The suppressant according to the third aspect of the present invention can be used, for example, as a therapeutic agent for diseases treatable by suppressing ovulation. Examples of diseases treatable by suppressing ovulation include diseases treated with low-dose oral contraceptives (low-dose pills). Examples of such diseases include endometriosis, dysmenorrhea, and premenstrual syndrome (PMS). That is, in one embodiment, the suppressant according to the third aspect of the present invention can be a therapeutic agent for endometriosis, a therapeutic agent for dysmenorrhea, and / or a therapeutic agent for premenstrual syndrome (PMS).
[0048] The inhibitor according to the third aspect of the present invention can be used, for example, as a preventive agent for diseases that can be prevented by suppressing ovulation. Examples of diseases that can be prevented by suppressing ovulation include diseases that are prevented by low-dose oral contraceptives (low-dose pills). Examples of such diseases include cervical cancer and ovarian cancer. That is, the inhibitor according to the third aspect of the present invention can be, in one embodiment, a preventive agent for cervical cancer and / or a preventive agent for ovarian cancer.
[0049] The suppression of ovulation by the inhibitor according to the third aspect of the present invention can be evaluated, for example, by administering the inhibitor to a control and suppressing ovulation. The suppression of ovulation by the inhibitor according to the third aspect of the present invention can be evaluated, for example, by administering the inhibitor to a control and suppressing ovulation, and the suppression of ovulation can be evaluated, for example, by a decrease in the rate of mature oocytes showing a phenotype of a sign of ovulation in the total number of oocytes and mature oocytes of the subject. For example, since a follicular membrane is formed in mature oocytes immediately before ovulation, the suppression of ovulation can be evaluated, for example, by a decrease in the rate of mature oocytes that have formed a follicular membrane in the total number of oocytes and mature oocytes of the subject to which the inhibitor is administered.
[0050] A fourth aspect of the present invention is a contraceptive (also called a contraceptive composition) comprising 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, co-crystal, polymorph, prodrug, or metabolite thereof as an active ingredient.
[0051] The fourth aspect of the present invention may, in one embodiment, be an antagonist according to the first aspect of the present invention, an inhibitor according to the second aspect of the present invention, or an inhibitor according to the third aspect of the present invention, used for contraception. In sexually reproducing vertebrates, an ovulated mature egg cell is fertilized with a spermatozoon, which is a male gamete, to form a fertilized egg, which eventually results in pregnancy. Thus, the antagonist according to the first aspect of the present invention, the inhibitor according to the second aspect of the present invention, or the inhibitor according to the third aspect of the present invention can inhibit ovulation of a mature egg cell as described above, and therefore can also be used as a contraceptive.
[0052] The antagonist according to the fourth aspect of the present invention may be similar to those according to the first aspect of the present invention in terms of the administration target, administration mode, dosage form and dosage amount.
[0053] The contraceptive according to the fourth aspect of the invention may be used, for example, for contraception in a human subject.
[0054] The contraceptive according to the fourth aspect of the present invention may be used to prevent reproduction in pet animals, for example dogs, cats and rabbits.
[0055] The contraceptive according to the fourth aspect of the present invention can be used, for example, to reduce production and promote growth in aquaculture, livestock and poultry farming. In aquaculture, livestock and poultry farming, if an animal becomes pregnant unintentionally, not only will it cause an unregulated increase in production, but it will also cause growth inhibition of the female parent as nutrients are used for the development of an individual from a fertilized egg. Thus, by preventing pregnancy with the contraceptive according to the fourth aspect of the present invention, it is possible to suppress such unregulated increase in production and growth inhibition.
[0056] The contraceptive effect of the contraceptive according to the fourth aspect of the present invention means that the pregnancy rate is reduced by 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more compared to the pregnancy rate in women of the same age (in the case of fish, females of the same month or age) without the use of the contraceptive.
[0057] Methods and Use
[0058] The fifth aspect of the present invention may also be a method for competitively inhibiting a progestin membrane receptor, comprising administering to a subject in need thereof an effective amount of 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof. The fifth aspect of the present invention may also be a method for inhibiting the formation of mature oocytes, comprising administering to a subject in need thereof an effective amount of 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof. Furthermore, the fifth aspect of the present invention may also be a method for inhibiting ovulation, comprising administering to a subject in need thereof an effective amount of 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug, or metabolite thereof.
[0059] The sixth aspect of the present invention may be 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof for use in competitively inhibiting progestin membrane receptors. The sixth aspect of the present invention may also be 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof for use in inhibiting the formation of mature oocytes. The sixth aspect of the present invention may also be 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof for use in inhibiting ovulation.
[0060] The seventh aspect of the present invention may also be the use of 2-hydroxypentanoic acid or its salts, esters, tautomers, isotope-labeled compounds, solvates, cocrystals, polymorphs, prodrugs or metabolites for the manufacture of an antagonist of a progestin membrane receptor. The seventh aspect of the present invention may also be the use of 2-hydroxypentanoic acid or its salts, esters, tautomers, isotope-labeled compounds, solvates, cocrystals, polymorphs, prodrugs or metabolites for the manufacture of an inhibitor of the formation of mature oocytes. Furthermore, the seventh aspect of the present invention may also be the use of 2-hydroxypentanoic acid or its salts, esters, tautomers, isotope-labeled compounds, solvates, cocrystals, polymorphs, prodrugs or metabolites for the manufacture of an inhibitor of ovulation. EXAMPLES
[0061] The present invention will be described in more detail below using examples, but the present invention is not limited to the following examples.
[0062] <Example 1: Isolation of components contained in sea fan secretions> A polyester filter (JAN code 4972814531680, KOTOBUKI) was placed in an aquarium where sea fans (Padina arborescens) were kept, and the sea fan secretions were trapped on the filter. The trapped secretions were eluted with 1 liter of ethanol per filter. The resulting solution was diluted 10 times with ultrapure water to obtain a sample, which was then fed to an ODS column (50 μm, 1.8 × 11.4 cm, 7 g, Yamazen Corporation) using a roller pump to load the sea fan secretions onto the ODS column. 10 to 20 liters of sample were used per ODS column.
[0063] The secretions loaded onto the ODS column were separated by reversed-phase liquid chromatography by supplying a gradient of a water-acetonitrile mixture (100:0-0:100) to the secretions loaded onto the ODS column under acidic conditions in the presence of 0.05% trifluoroacetic acid. The obtained fraction was further loaded onto an ODS column (4.6 x 30 cm, Tosoh Corporation) and a gradient of a water-acetonitrile mixture (100:0-0:100) was supplied to the secretions by reversed-phase liquid chromatography. The obtained fraction was further loaded onto a TSKgel Protein A-5PW RP Glass (8 mm x 7.5 cm) column (Tosoh Corporation) and a gradient of a water-acetonitrile mixture (100:0-0:100) was supplied to the secretions by reversed-phase liquid chromatography. The elution of the substances in these chromatographies was monitored by absorbance at 254 nm, and the temperature was kept at 40°C.
[0064] The results of the chromatography are shown in Figure 1. As shown in Figure 1, two peaks, Peak 1 and Peak 2, were detected. This result also demonstrated that the components contained in sea fan secretions can be isolated by this isolation method.
[0065] <Example 2: Test of inhibition of oocyte maturation by components contained in sea fan secretions> The fractions corresponding to Peak 1 and Peak 2 isolated in Example 1 were dried using a freeze dryer (FDU-810 freezedryer, manufactured by EYELA) to obtain isolated fractions corresponding to Peak 1 and Peak 2 (hereinafter sometimes simply referred to as "Peak 1 isolated fraction" and "Peak 2 isolated fraction"). The isolated fractions were tested for oocyte maturation inhibitory activity.
[0066] Ovaries isolated from fertilized female zebrafish without ovulated mature oocytes were manually separated into ovarian fragments containing 2-10 oocytes. The resulting ovarian fragments were cultured in zebrafish Ringer's solution (5 mM HEPES buffer containing 116 mM NaCl, 2.9 mM KCl, 1.8 mM CaCl2, pH 7.2) containing 1 μM 17α,20β-dihydroxyprogesterone (DHP) or 1 μM DHP and 1 μM test substance (Peak 1 isolate or Peak 2 isolate described above). Culture was performed at 25°C for 2-4 hours with gentle agitation. The ovarian fragments were then imaged under an optical microscope to assess the maturity of oocytes by evaluating germinal vesicle breakdown (GVBD). GVBD was evaluated based on the percentage of cleared oocytes among more than 20 oocytes in each group.
[0067] The results for the Peak 1 isolate and the Peak 2 isolate are shown in Figure 2, A and B, respectively. As shown in Figure 2, germinal vesicle breakdown induced in the presence of DHP was suppressed in the presence of Peak 1 or Peak 2 isolate. This indicates that Peak 1 and Peak 2 isolates can inhibit oocyte maturation. This also indicates that the test method can be used to evaluate the inhibition of oocyte maturation by components contained in sea fan secretions.
[0068] <Example 3: Test of inhibition of oocyte maturation and ovulation in zebrafish by components contained in sea fan secretions> Fertilized female zebrafish with fully grown immature oocytes were pre-treated with DHP to induce spawning. The spawned female zebrafish were then raised for an additional 7-10 days to produce new fully grown immature oocytes. On the day of the experiment, non-ovulating females were selected and used in the experiment.
[0069] Selected female zebrafish were transferred to an aquarium containing 100 mL of water per fish. DHP at a final concentration of 100 nM, or isolated products of DHP and Peak2 at a final concentration of 100 nM, were added thereto, and incubated at 28.5 °C under room light conditions for 4 hours. After sacrificing the female zebrafish, the ovaries were isolated. The isolated ovaries were manually separated into ovarian fragments containing 1 to 10 oocytes. The obtained ovarian fragments were photographed under an optical microscope, and oocyte maturation and ovulation were evaluated. Oocyte maturation was evaluated using the percentage of cleared oocytes in more than 20 oocytes in each group as an index of the occurrence of GVBD. Ovulation was evaluated using the percentage of cells with clear egg membranes as an index.
[0070] The results are shown in Figure 3. In the figure, ** means that the p value in the Student's t-test is less than 0.01. As shown in Figure 3, oocyte maturation and ovulation induced in zebrafish raised in the presence of DHP were suppressed in the presence of Peak2 isolates, and in particular, the proportion of cells that formed a chorion was significantly reduced. This indicates that Peak2 isolates can inhibit oocyte maturation and ovulation in individual animals.
[0071] Example 4: Analysis of components contained in sea fan secretions The isolated product of Peak 2 obtained in the Example was analyzed for its components by nuclear magnetic resonance. The isolated product of Peak 2 was dissolved in 500 μL of CDCl3, and NMR was measured. 1 H, 13 NMR spectral data, including C, DQF-COSY, TOCSY, HMQC, and HMBC, were measured using a JNM-ECZ500R spectrometer (JEOL, Tokyo, Japan).
[0072] 1 H-NMR, 13The results of C-NMR, DQF-COSY, TOCSY, HMQC and HMBC are shown in Figures 4 to 9, respectively. From the results of Figures 4 to 9, based on the correlations of DQF-COSY, TOCSY, HMQC and HMBC of two-dimensional NMR, it was presumed that the isolated product of Peak 2 was 2-hydroxypentanoic acid (2-HPA). This also demonstrated that the isolation method of Example 1 can isolate components contained in sea fan secretions to an extent that allows analysis.
[0073] <Example 5: Test for inhibition of oocyte maturation by (R)-2-HPA and (S)-2-HPA> The 2-HPA found in Example 4 exists as enantiomers, (R)-2-HPA and (S)-2-HPA. Therefore, the same test as in Example 2 was performed using (R)-2-HPA (manufactured by AMATEK CHEMISTRY) and (S)-2-HPA (manufactured by Combi-Blocks) instead of the Peak 2 isolate, and the inhibition of oocyte maturation was evaluated.
[0074] The results are shown in FIG. 10. In the figure, * means that the p-value in the Student's t-test between the DHP group is less than 0.05. The results in FIG. 10 show that both (R)-2-HPA and (S)-2-HPA inhibit oocyte maturation, strongly suggesting that both (R)-2-HPA and (S)-2-HPA are mPR antagonists. In addition, based on the above results, in the examples from Example 6 onwards, (S)-2-HPA was used as 2-HPA.
[0075] Example 6: Evaluation of specific binding of 2-HPA and its related compounds to mPR The binding ability of 2-HPA and its related compounds to mPR was evaluated according to the method described in Non-Patent Document 8 (GQD binding assay). The GQD binding assay is an assay to evaluate the binding ability of a substance to mPR using mPR (GQD-mPRα) to which graphene quantum dots (GQD) have been added, progesterone (P4) which is a ligand of mPR, and bovine serum albumin labeled with the fluorescent dye FITC (P4-BSA-FITC). When GQD-mPRα, P4-BSA-FITC, and a substance to be evaluated are allowed to coexist, if the substance to be evaluated has binding ability to mPR, the binding between GQD-mPRα and P4-BSA-FITC is competitively inhibited, and fluorescence resonance energy transfer (FRET) is suppressed, resulting in a decrease in the intensity of the fluorescence derived from FITC when the excitation light corresponding to GQD is irradiated. In other words, when GQD-mPRα, P4-BSA-FITC, and the substance to be evaluated are allowed to coexist, if the fluorescence intensity derived from FITC decreases in a concentration-dependent manner of the substance to be evaluated, the substance can be evaluated as having mPR binding properties.
[0076] mPR was purified by affinity chromatography from genetically engineered cells into which a gene encoding mPR was introduced, according to the method described in Patent Document 1. 2 μL of ethanol containing the substance to be evaluated was added to each well of a 96-well microplate so that the final concentration was the value shown in the figure. 98 μL of a phosphate buffer solution at pH 7.4 containing GQD-mPRα prepared according to the method described in Non-Patent Document 8 at a final concentration of 9 μg / mL based on the mPRα concentration and P4-BSA-FITC at a final concentration of 14 μg / mL based on the BSA concentration was added thereto, and incubated at room temperature for 2 hours under light-shielded conditions. Thereafter, the fluorescence intensity of each well was measured using a microwell plate reader (Varioskan (registered trademark) LUX, manufactured by Thermofisher Scientific). The excitation wavelength in the fluorescence intensity measurement was 370 nm, and the fluorescence wavelength was 520 nm.
[0077] The evaluation results are shown in Figure 11. The isolated product of Peak 2 containing 2-HPA as the main component isolated in Example 1 ("Padina-C" in Figure 11), pure product of (S)-2-HPA (manufactured by Combi-Blocks, "(S)-2-HPA" in Figure 11), 2-hydroxybutyric acid (2-Hydroxybutyric acid, manufactured by Tokyo Chemical Industry Co., Ltd.), valeric acid (pentanoic acid, manufactured by Tokyo Chemical Industry Co., Ltd.), 2-hydroxyhexanoic acid (2-Hydroxyhexanoic acid, manufactured by Sigma-Aldrich Co., Ltd.), 1,2-pentanediol, and 3-hydroxybutyric acid (3-Hydroxyvaleric acid, manufactured by AdooQ BioScience Co., Ltd.), as well as progesterone, a known mPR-binding hormone, and estradiol, a mPR-non-binding hormone, as positive controls, were evaluated. As shown in Figure 11, the fluorescence intensity of the isolated Peak 2, which is mainly composed of 2-HPA, and the pure (S)-2-HPA decreased in a concentration-dependent manner, and showed the same level of activity as the positive controls progesterone and estradiol. Contrary to expectations, no decrease in fluorescence intensity was observed in 2-HPA related compounds such as 2-hydroxybutyric acid. Of the 2-HPA and its related compounds tested in this study, only 2-HPA has mPR binding ability, suggesting that the binding of 2-HPA to mPR is specific and dependent on the structure of 2-HPA. [ka]
[0078] <Example 7: Inhibition of oocyte maturation and ovulation by 2-HPA in zebrafish> A similar test to that in Example 3 was carried out using (S)-2-HPA instead of the Peak 2 isolate to assess oocyte maturation and ovulation.
[0079] The results are shown in FIG. 12. In the figure, ** means that the p value in the Student's t-test is less than 0.01. As shown in FIG. 12, the maturation and ovulation of oocytes induced in zebrafish raised in the presence of DHP were suppressed in the presence of (S)-2-HPA, and in particular, the percentage of cells that formed a chorion was significantly reduced. This indicates that 2-HPA can inhibit the maturation and ovulation of oocytes in individual animals. Furthermore, since it is considered that it is possible to inhibit fertilization if the maturation and ovulation of oocytes can be inhibited, it was strongly suggested that 2-HPA can inhibit fertilization and pregnancy in individual animals, that is, that it can be used as a contraceptive drug.
[0080] <Example 8: Maturation inhibition test of 2-HPA and its analogues using goldfish oocytes> A similar test to that in Example 2 was performed using goldfish oocytes prepared according to the method described in Non-Patent Document 9 instead of zebrafish oocytes, and using 2-hydroxybutyric acid (Tokyo Chemical Industry Co., Ltd.), valeric acid (pentanoic acid, Tokyo Chemical Industry Co., Ltd.), 2-hydroxyhexanoic acid (Sigma-Aldrich), 1,2-pentanediol, and 3-hydroxyvaleric acid (AdooQ BioScience) in addition to (S)-2-HPA instead of the isolated Peak2.
[0081] The results are shown in Figure 13. In Figure 13, ** means that the p-value in the Student's t-test between the DHP group and the control group is less than 0.01. Figure 13 shows that, among the 2-HPA and its analogues tested in this study, only 2-HPA can inhibit oocyte maturation.
[0082] <Example 9: Test of inhibition of oocyte maturation and ovulation by 2-HPA and its analogues in zebrafish> A test similar to that of Example 7 was carried out using 2-hydroxybutyric acid (manufactured by Tokyo Chemical Industry Co., Ltd.), valeric acid (pentanoic acid, manufactured by Tokyo Chemical Industry Co., Ltd.), 2-hydroxyhexanoic acid (manufactured by Sigma-Aldrich), 1,2-pentanediol, and 3-hydroxybutyric acid (manufactured by AdooQ BioScience) in addition to (S)-2-HPA.
[0083] The results are shown in Figure 14. In Figure 14, ** means that the p-value in the Student's t-test between the DHP group and the control group is less than 0.01. Figure 14 shows that, among the 2-HPA and its analogous compounds tested in this study, only 2-HPA can inhibit oocyte maturation and ovulation in individual animals.
Claims
1. Antagonists of progestin membrane receptors comprising 2-hydroxypentanoic acid or a salt, ester, tautomer, isotopically labeled compound, solvate, co-crystal, polymorph, prodrug or metabolite thereof.
2. An inhibitor of the formation of mature oocytes, comprising 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof.
3. An ovulation suppressant comprising 2-hydroxypentanoic acid or a salt, ester, tautomer, isotope-labeled compound, solvate, cocrystal, polymorph, prodrug or metabolite thereof.
4. The drug according to any one of claims 1 to 3, which is used for contraception.
Citation Information
Patent Citations
Method for purifying steroid hormone membrane receptors
JP2015010064A
